Bristol-Myers Squibb to Present at Healthcare Conference

Business Wire,  May 7, 2008  

Tags: Bristol-Myers Squibb Co., health care

• E-mail
• Print
• Link

* Will Reaffirm 3-Year 15% Compound Annual Growth Rate of Earnings Per Share

* Expects to Update 2008 Earnings Guidance No Later Than End of Second Quarter

NEW YORK -- Bristol-Myers Squibb Company (NYSE:BMY) will present today at the 33rd Annual Deutsche Bank Healthcare Conference. Lamberto Andreotti, Executive Vice President and Chief Operating Officer, will make a formal presentation on the company at 10:10 a.m. ET.

At the presentation, Mr. Andreotti will reaffirm guidance that the company expects non-GAAP earnings per share from continuing operations to grow at a minimum of 15 percent compounded annual growth rate, from the 2007 base through 2010 without rebasing for the recently announced agreement to sell its ConvaTec business unit, excluding costs associated with the Productivity Transformation Initiative and other specified items that have not yet been identified and quantified.

This financial guidance also excludes the impact of any potential strategic acquisitions and divestitures and further assumes that the company and its product partner, sanofi-aventis, maintain exclusivity for the PLAVIX([R]) patent through at least 2010. There is no reasonably accessible or reliable comparable GAAP measure for this forward-looking information on earnings per share.

The Company is evaluating its 2008 full-year guidance and is not reaffirming it at this time. In 2007, ConvaTec contributed approximately $0.12 to the Company's full-year fully diluted earnings per share.

Investors and the general public are invited to listen to a live webcast of the presentations at http://www.bms.com/ir. Materials related to the presentations will be available at the same website at the start of each live webcast. An archived edition of each presentation will be available later that day.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, (including whether uncertainties in the credit and capital markets or a further deterioration of these markets will lead to future impairments to the company's investment portfolio) competitive product development, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical rebates and reimbursement, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, difficulties and delays in product development, manufacturing or sales, patent positions and the ultimate outcome of any litigation matter, including whether Apotex will prevail in its appeal of the District court's decision in the PLAVIX([R]) patent litigation. These factors also include the company's ability to execute successfully its strategic plans, including its productivity transformation initiatives, the expiration of patents or data protection on certain products, and the impact and result of governmental investigations. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning